Welcome to our dedicated page for Know Labs news (Ticker: KNW), a resource for investors and traders seeking the latest updates and insights on Know Labs stock.
The news archive for Know Labs, Inc. (historically NYSE American: KNW) captures the company’s evolution from a developer of radio frequency dielectric spectroscopy (RFDS) technology for non‑invasive diagnostics to its later transition under the USBC, Inc. name and USBC ticker. Company news releases describe how its RFDS platform directs electromagnetic energy through substances or materials to capture unique molecular signatures, supporting applications such as non‑invasive glucose monitoring and contactless pH measurement.
Readers can review announcements on technology milestones, including laboratory research showing that the company’s RFDS sensor can detect pH changes in real time without direct contact with a liquid, and updates on efforts to advance a non‑invasive blood glucose monitor toward potential FDA clearance. News items also discuss the launch and objectives of Know Labs Technology Licensing (KTL), the division that licenses RFDS technology and the proprietary e‑RFDS© digital watermark to corporations, universities, and research institutions.
The KNW news history further documents significant corporate and capital markets events. These include the 1‑for‑40 reverse stock split effective February 19, 2025, the temporary move to trading on the OTC Pink Market under KNWN while appealing NYSE American delisting proceedings, and subsequent financing and governance developments. Later releases cover the Securities Purchase Agreement with Goldeneye 1995 LLC, the resulting change in control, shareholder approvals to increase authorized common stock and amend the equity incentive plan, and the eventual change of corporate name to USBC, Inc. and trading symbol to USBC.
By browsing this news feed, investors and researchers can trace how Know Labs combined RFDS‑based diagnostic research and licensing with a later strategy that includes a Bitcoin treasury approach and the development of the USBC token, as outlined in joint announcements with Greg Kidd and related SEC filings.
Know Labs, Inc. (KNW) has announced successful results from a proof-of-principle study demonstrating the accuracy of its proprietary Bio-RFID technology in non-invasive medical diagnostics. Conducted in collaboration with Mayo Clinic, the study, titled "Detecting Unique Analyte-Specific Radio Frequency Spectral Responses in Liquid Solutions," showcased a remarkable 100% accuracy rate in measuring various analytes in vitro. This breakthrough technology captures molecular signatures using radio waves, with glucose monitoring being its first application. Market trends highlighting the need for affordable, accurate non-invasive healthcare solutions further bolster the significance of these results. The full study awaits peer-review publication.
Know Labs, Inc. (NYSE American: KNW) has formed a new Scientific Advisory Board (SAB) featuring leading experts in medical technology and human health. This board aims to enhance Know Labs' efforts in algorithm refinement, device development, and clinical trial design for its Bio-RFID technology, which aims to offer non-invasive glucose monitoring. The SAB includes esteemed members like Dr. Benjamin Smarr and Dr. Mark Aloia, who bring extensive backgrounds in research and technology. Know Labs emphasizes 2023 as a year of prioritizing external validation of its non-invasive diagnostic technology.
FAQ
What is the current stock price of Know Labs (KNW)?
What is the market cap of Know Labs (KNW)?
